Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives $16.38 Average PT from Analysts
Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month price […]
Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month price […]
